JWH-073

cardiac arrhythmia, structural heart disease, coronary artery disease

Multiple case reports document cardiovascular adverse events associated with JWH-073-containing products, including tachycardia progressing to bradycardia, ST-elevation myocardial infarction (STEMI), subarachnoid hemorrhage, and reversible cardiomyopathy. Tachycardia is the most common adverse presentation across synthetic cannabinoid case series (37–77% incidence). Pre-existing cardiac conditions elevate the risk of life-threatening cardiovascular events.

epilepsy, seizure disorder, history of seizures

JWH-073 at doses exceeding 1 mg/kg produces seizures, myoclonia, and hyperreflexia in mice, all blocked by CB1 antagonist AM251, confirming CB1-mediated seizure threshold reduction. Human case reports document generalized tonic-clonic seizures in users of JWH-073-containing products. Individuals with pre-existing seizure disorders face compounded risk.

psychosis, schizophrenia, schizoaffective disorder

JWH-073 is a full CB1 agonist with no accompanying cannabidiol (CBD). Full agonism at CB1 produces greater receptor activation than partial agonists like THC, and the absence of CBD removes a potential psychosis-moderating factor present in cannabis. Case reports document acute psychosis with paranoia, delusions, hallucinations, and severe agitation in users of products containing JWH-073. One fatal case involved extreme psychiatric decompensation resulting in self-inflicted lethal injury.

pregnancy, breastfeeding

No reproductive, teratogenic, or developmental toxicity studies have been published for JWH-073 in any species. Given the compound's high CB1 affinity (Ki = 8.9 nM) and full agonist status, exposure during pregnancy or breastfeeding poses unknown but potentially severe risks to fetal and neonatal endocannabinoid system development. Absolute contraindication is applied by precautionary principle in the absence of safety data.

adolescent use, young adult use

Case series identify younger users as disproportionately represented in severe synthetic cannabinoid adverse events. The endocannabinoid system undergoes developmental changes during adolescence, and full CB1 agonist exposure during this period may produce greater disruption than in mature systems. The first laboratory-confirmed cardiotoxicity case involved a 17-year-old.

cocaine use, amphetamine use, stimulant use

JWH-073 stimulates mesolimbic dopamine release via CB1 activation. Co-administration with sympathomimetic substances (cocaine, amphetamines, other stimulants) may produce additive or synergistic cardiovascular stress including tachycardia, hypertension, and increased myocardial oxygen demand. No clinical interaction data exist for JWH-073 with specific sympathomimetics, but the pharmacological mechanism supports elevated risk.